Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06701578

The Effect of the Safe and Sound Protocol on Depression and Anxiety Symptoms

The goal of this study is to determine if a developed protocol involving modulated auditory stimulation is better than non-modulated auditory stimulation in reducing anxiety and depression in human subjects.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Regions Hospital

Saint Paul, Minnesota, 55101, United States

Location contact

Peggy Ninow

CONTACT

[email protected]

651-254-6836

Peggy Ninow

PRINCIPAL_INVESTIGATOR

About this study

A protocol has been developed that provides patients an intervention of listening to specifically designed filtered and modulated music that stimulates the part of the nervous system that induces a calm physiological (bodily) state. This enhancement may help re-establish nerve pathways between auditory processing and emotional regulation systems which promotes improved emotional regulation in regards to depression and anxiety. For this study, participants will either be assigned to the active group who receives the therapy with auditory stimulation that is modulated, or be assigned to the control group who will receive the same interventions without the modulated auditory stimuli.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Client of DayBridge
  • 18 years old or older
  • Meet the DMS-V diagnostic criteria of Major Depressive Disorder and/or Generalized Anxiety Disorder

Exclusion criteria

  • Previous participation in the SSP
  • Self-reported hearing loss

Treatment and study plan

Safe and Sound Protocol

Other

Listening to specially designed filtered and modulated music that is tailored to enhance the individual's auditory system's ability to process and respond to auditory stimuli for up to five hours.

Control

Other

Listening to music that is not filtered and modulated for up to five hours.

Primary outcomes

  1. PHQ-9

    Time frame: 10 minutes at enrollment visit and 10 minutes at final study visit 3 weeks after enrollment

    The 9-question Patient Health Questionnaire (PHQ-9) is a self-report screening tool for adults in primary care settings for assessing the presence and severity of depression symptoms. Items are aligned with the DSM-5 diagnostic criteria for MDD and queries the individual's experience in the past two weeks. Likert-type responses range from 0 ("Not at all") to 3 ("Nearly every day"). Good reliability and validity have been demonstrated. The PHQ-9 score is the key outcome variable for MDD symptoms.

    The total score is obtained by summing the values of the seven items. The total score ranges from 0 to 27, with higher scores indicating greater severity of depressive symptoms.

  2. GAD-7

    Time frame: 10 minutes at enrollment visit and 10 minutes at final study visit 3 weeks after enrollment.

    The Generalized Anxiety Disorder 7 (GAD 7) is a self-administered measure of the frequency and severity of generalized anxiety disorder symptoms based on seven DSM-5 diagnostic criteria for GAD. It is typically used in outpatient and primary care settings. Response options are a Likert-type scale ranging from 0 ("Not at all") to 3 ("Nearly every day"). An additional question is a global rating of the severity of the patient's anxiety over the past 2 weeks. The measure is considered sensitive and has shown adequate internal consistency reliability and validity for assessing anxiety across a wide range of samples and settings. The GAD-7 score is the key outcome variable for GAD symptoms.

    The scoring involved summing the values of all seven items to obtain a score between 0 and 21. Higher scores indicate greater severity of anxiety symptoms.

  3. BPQ-SF

    Time frame: 10 minutes at enrollment visit and 10 minutes at final study visit 3 weeks after enrollment.

    The Body Perception Questionnaire - Short Form (BPQ-SF) is an abbreviated version of the original self-report measure of body awareness and autonomic reactivity. The questionnaire consists of two subscales, Body Awareness (26 items) and Autonomic Nervous System Reactivity (20 items). The Likert-type scale answers range from 1 ("Never") to 5 ("Always"). Total scores for each subscale, which are key outcome variables, are summed and compared to T-scores in the BPQ Manual.

  4. Heart Period and Respiratory Sinus Arrhythmia

    Time frame: 10 minutes at enrollment visit and 10 minutes at final study visit 3 weeks after enrollment.

    Heart period will be recorded at 1000 Hz using a Polar H10 chest strap device. This device has shown strong agreement and small bias compared to electrocardiogram (ECG) recordings. It has been chosen as it is minimally invasive and easy for participants to put on.

    RSA and heart period will be used to calculate the vagal contribution to regulation of the heart, i.e., vagal tone.

Study contacts

Contact information is provided by the study sponsor or research team.

Michelle Leal

CONTACT

[email protected]

+27662496829

Peggy Ninow

CONTACT

[email protected]

651-254-6836

Sponsors and collaborators

Lead sponsor

HealthPartners Institute

Other

Registry information

Acronym: SSP

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Nov 22, 2024
Registry last updated
Jul 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.